Hair Loss & Scalp Health

Minoxidil / GHK-Cu / Apigenin / Fisetin

A scalp-focused minoxidil combination with emerging cosmetic and botanical ingredients.

Evidence brief in review

lennoxHAIRProduct image pending

Common goals: Potential minoxidil-centered support for selected hair and scalp goals.
Best program fit: May fit a monitored scalp-health offering that clearly separates minoxidil evidence from the less-established added ingredients.
Format: Compounded combination · exact dosage form to be confirmed

Partner education guide

Where this may fit in an offering.

Potential minoxidil-centered support for selected hair and scalp goals. One compounded format may simplify a multi-ingredient routine. May fit a premium scalp-health offering with careful outcome photography.

Educational business-planning summary. Potential benefits vary, are not guaranteed, and require individual-specific clinical review.

01 / Common goals

What people may want to understand.

Primary goals

Potential benefits and goals

Potential minoxidil-centered support for selected hair and scalp goals.
One compounded format may simplify a multi-ingredient routine.
GHK-Cu and botanical ingredients provide an emerging scalp-care rationale.

Program value

How it may support a program

May fit a premium scalp-health offering with careful outcome photography.
Encourages a clear distinction between established minoxidil evidence and exploratory ingredients.

The exact combination has no product-matched clinical trial. Benefits beyond minoxidil are uncertain and outcomes are not guaranteed.

02 / Program fit

Program and operational considerations.

01Administration format: Catalog format: Compounded combination · exact dosage form to be confirmed. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.
02Typical frequency: The screenshot does not establish a schedule. Frequency must come from the exact prescription and route-specific product instructions.
03Expected duration: Hair-loss treatment is usually assessed over months and often requires continued use to maintain benefit. The exact combination has no product-matched duration study.
04Practical considerations: May fit a premium scalp-health offering with careful outcome photography.

03 / Suitability considerations

Who may be considered.

Who may be considered

A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
An individual willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

Qualification notes

May fit a premium scalp-health offering with careful outcome photography.
Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

04 / Safety & suitability

What must be screened before treatment.

Common or temporary

Topical minoxidil may cause scalp irritation, dryness, itching, unwanted facial hair, or early shedding.
The frequency of reactions to the exact GHK-Cu, apigenin, and fisetin combination is unknown; compounded excipients can also irritate the scalp.

Serious or important

Chest pain, fainting, significant swelling, shortness of breath, rapid heartbeat, severe rash, or facial swelling requires prompt assessment.
Long-term systemic exposure and interaction risks for the exact combination are not established.

Avoid or use only with specialist input

Unexplained, sudden, patchy, scarring, infected, inflamed, or painful scalp conditions until assessed.
Pregnancy, breastfeeding, pediatric use, significant cardiovascular disease, known ingredient allergy, or unverifiable product identity without qualified review.

Screening checklist

Confirm the hair-loss pattern and duration, scalp findings, family history, current medicines and supplements, blood-pressure and heart history, reproductive plans, sexual symptoms, mood history, and relevant laboratory evaluation.
Verify the exact dosage form, route, ingredient strengths, dispensing pharmacy, storage, and how progress will be photographed or measured.

When to refer

Refer for dermatology or medical assessment when hair loss is sudden, patchy, scarring, associated with inflammation or systemic symptoms, occurs in a child, or remains diagnostically unclear.
Prompt assessment is appropriate for chest pain, syncope, marked edema, a persistent rapid heartbeat, severe scalp reaction, pregnancy exposure, or significant sexual or mood symptoms.

Safety information is not exhaustive. Prescribing, screening, dosing, monitoring, and emergency guidance must come from an appropriately licensed clinician and the exact product information.

What the research says · reviewed August 2026

Research and source context.

The strongest clinical footing comes from minoxidil. Evidence for adding GHK-Cu, apigenin, and fisetin to this exact scalp product is limited.

01 / Human research

The clearest clinical signal

Topical minoxidil has labeled hair-regrowth evidence. GHK-Cu literature is mainly cosmetic skin research, while the full four-ingredient scalp combination lacks a controlled human trial.

02 / Real-world reports

What people describe

People may be interested in an all-in-one scalp formula, but should understand which ingredient has direct hair-regrowth evidence and which ingredients remain exploratory.

Public personal accounts are unverified and cannot show how common an outcome is.

03 / Cautions

What deserves attention

Unknown ingredient concentrations, scalp irritation, allergy, systemic minoxidil exposure, and compounded-product quality require monitoring.

Does the research match this exact product?

No. Available evidence does not directly test this exact formulation, route, or ingredient concentrations.

Complete evidence briefClinical summary, safety notes, reported timing, regulatory context, and linked sources in one document.

Evidence brief in reviewReviewed sources are listed above

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

Education before offering.

Treatment information is for education only. It is not medical advice. A licensed clinician will review your health and decide whether a treatment is appropriate for you. Eligibility and availability may vary.

Back to all treatments